Last reviewed · How we verify
Single Ascending Dose of SAB-176
At a glance
| Generic name | Single Ascending Dose of SAB-176 |
|---|---|
| Also known as | SAB-176 |
| Sponsor | SAb Biotherapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants (PHASE1)
- A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single Ascending Dose of SAB-176 CI brief — competitive landscape report
- Single Ascending Dose of SAB-176 updates RSS · CI watch RSS
- SAb Biotherapeutics, Inc. portfolio CI